Risk factors and antimicrobial resistance of ESBL-positive Enterobacter cloacae complex bloodstream infections: a retrospective clinical and molecular study

In the crowded, high-stakes environment of a modern hospital, the human body often faces a silent battle against microscopic invaders. Among these, a group of bacteria known as the Enterobacter cloacae complex is a frequent and formidable opponent. These are opportunistic germs, meaning they usually wait for a moment of weakness—such as a severe illness, a surgical wound, or a medical device like a catheter—to slip into the bloodstream and cause infection. When these bacteria enter the blood, the condition is called a bloodstream infection, a serious medical event that can rapidly turn life-threatening. The primary weapon doctors use to fight these infections is antibiotics. However, bacteria are clever and adaptable; over time, they can develop defenses that render these medicines useless. One of the most common and dangerous defenses is the production of enzymes called extended-spectrum beta-lactamases, or ESBLs. These enzymes act like molecular scissors, snipping apart many types of antibiotics before they can kill the bacteria. When a patient is infected with ESBL-producing bacteria, the standard treatments often fail, leaving doctors with very few options and forcing them to use stronger, more toxic drugs. Understanding who is most likely to get these resistant infections and how the bacteria behave is critical for keeping patients safe.

A team of researchers at the First Affiliated Hospital of Nanchang University in China set out to understand this specific problem in their local hospital. They looked back at medical records and bacterial samples collected over a four-year period, from 2021 to 2024. Their focus was on 64 patients who had developed bloodstream infections caused by the Enterobacter cloacae complex. The researchers divided these patients into two groups: those whose bacteria were resistant to many common antibiotics because they carried the ESBL defense, and those whose bacteria did not. By comparing the medical histories of these two groups, the team sought to find patterns that could predict who was at risk. They also examined the bacteria under a microscope and in a lab to see exactly which genes they carried, how they reacted to different drugs, and how they were related to one another genetically.

The study revealed a clear and concerning picture. Out of the 64 patients, 21 were infected with the ESBL-positive version of the bacteria, representing about one-third of all cases. When the researchers compared the patients with these resistant infections to those with the non-resistant kind, a distinct pattern emerged regarding their time in the hospital. Patients with the resistant bacteria had stayed in the hospital significantly longer, averaging about 16 days, compared to roughly 8 days for the others. They were also much more likely to have been admitted to the intensive care unit and to have had a urinary catheter inserted. While having a catheter or being in the ICU were factors that appeared more often in the resistant group, statistical analysis showed that the length of the hospital stay was the strongest independent predictor. In simple terms, the longer a patient remained in the hospital, the higher their chance was of encountering these specific, hard-to-treat bacteria. This suggests that the hospital environment itself, with its constant exposure to antibiotics and medical devices, acts as a pressure cooker that selects for these tougher germs.

The bacteria themselves told an even more complex story of resistance. The team tested how the bacteria reacted to a wide array of antibiotics. The ESBL-positive bacteria were far more stubborn than their non-resistant cousins. They showed high levels of resistance to common drugs like gentamicin, ciprofloxacin, and even some of the newer, stronger antibiotics like piperacillin/tazobactam and imipenem. In fact, every single ESBL-positive isolate was completely resistant to two specific drugs, aztreonam and ceftriaxone. This means that for a patient infected with these bacteria, a large portion of the standard antibiotic arsenal would be ineffective. The researchers also looked for the specific genetic instructions that allowed the bacteria to resist drugs. They found that the genes responsible for the ESBL defense were present only in the resistant group. More alarmingly, they discovered that eight of the resistant bacteria also carried genes for carbapenemases, a different and even more powerful type of defense that can break down the "last resort" antibiotics used when other drugs fail. Most of these super-resistant bacteria carried a gene called NDM, which is known for spreading easily between different types of bacteria.

Beyond just drug resistance, the researchers wanted to know if these dangerous bacteria were also more aggressive or "virulent" than the others. They checked for genes that help bacteria stick to tissues, steal iron from the body, or form protective films. Surprisingly, they found no difference between the two groups. The bacteria that were hard to kill were not necessarily better at attacking the human body or causing more severe damage through their own biological tools. The danger came entirely from their ability to survive the medicines meant to stop them. The team also mapped the family trees of these bacteria using a specific genetic marker called hsp60. They found that the resistant bacteria tended to belong to a specific genetic family, while the non-resistant ones belonged to different families. This suggests that certain lineages of these bacteria might be particularly good at surviving in the hospital and picking up resistance genes, though the researchers noted that more study is needed to confirm if this is a strict rule or just a trend.

The findings of this study paint a clear picture of a growing challenge in hospital medicine. The bacteria causing these infections are not becoming more deadly in terms of their natural ability to harm the body, but they are becoming increasingly difficult to treat because they are accumulating layers of resistance. The key takeaway for hospital staff is that time is a risk factor. A patient who has been in the hospital for a long time is at a higher risk of carrying these resistant bugs, and once infected, the treatment options are severely limited. The researchers concluded that to manage these infections, hospitals need to combine careful monitoring of how long patients stay, strict control of invasive devices like catheters, and rapid genetic testing to identify exactly which resistance genes are present. By understanding that prolonged hospitalization is a major driver of these infections, medical teams can better protect their most vulnerable patients and ensure that the right antibiotics are used before the bacteria have a chance to multiply and spread.